Navenibart to be commercialized by Neopharmed Gentili

A potential new medicine to treat HAE, called navenibart, will, subject to regulatory approval, be sold in Europe by Neopharmed Gentili, following a deal with BioCryst, the pharmaceutical company that is developing the medicine globally.

This announcement follows earlier announcements. In June 2025, the two companies signed a deal in which Neopharmed Gentili purchased BioCryst’s European business and took over the commercialization of berotralstat (Orladeyo). In a subsequent announcement, in January 2026, BioCryst confirmed it had purchased Astria Therapeutics, the company that originally developed navenibart.

Charlie Gayer, President and Chief Executive Officer of BioCryst, said: “We are excited to partner with Neopharmed Gentili once again to help bring innovative medicines to patients living with HAE in Europe. This deal enables both companies to build upon the strong foundation of Orladeyo and leverages Neopharmed Gentili’s expertise in Europe.”

Alessandro Del Bono, Chief Executive Officer of Neopharmed Gentili, said: “We are proud to further strengthen and expand our collaboration with BioCryst Pharmaceuticals through this strategic agreement for navenibart, reinforcing a partnership grounded in a shared commitment to delivering meaningful impact for people living with hereditary angioedema.”

(Source: BioCryst)